ARTICLE | Clinical News
Custirsen sodium: Phase III started
October 11, 2010 7:00 AM UTC
Teva and OncoGenex began the open-label, international Phase III SYNERGY trial to evaluate docetaxel/prednisone with or without weekly 640 mg IV custirsen in 800 patients. The trial is the second of 3...